Body composition
Does Ipamorelin Cause Weight Gain? The Evidence
The honest read on appetite, body weight, and lean-versus-fat — separating the ghrelin mechanism from what the studies actually measured.
The short answer
Does ipamorelin cause weight gain? The honest answer is: it can push in two directions at once, and there is no human trial that settles it. Ipamorelin works on the ghrelin receptor — the body's hunger switch — so it can increase appetite, and eating more is how appetite turns into weight [1]. That is the 'gain' direction. But ipamorelin also triggers a growth-hormone pulse, and growth hormone tends to favour lean tissue over fat, which is why people use it hoping to get leaner, not heavier. In animals, ipamorelin actually defended body weight under stress — it cut chemotherapy-driven weight loss by about 24% in ferrets [5]. So 'weight gain' is the wrong single frame: the research points to appetite effects, a GH-driven shift in body composition, and weight that may go up or down depending on what the GH pulse and the increased hunger do in a given person. None of it is established in a controlled human body-composition trial.
Why the mechanism cuts both ways
Ipamorelin's body-composition effect runs through two levers that don't point the same way. Lever one is appetite: as a ghrelin-receptor (GHS-R1a) agonist, it activates the same hunger pathway the natural hormone ghrelin uses, which is the basis for the increased hunger some users report [1]. More appetite, all else equal, means more intake and potential weight gain. Lever two is the growth-hormone pulse: GH biases the body toward building and preserving lean mass and mobilising fat, which is the opposite of fat gain. The 1998 founding study established that ipamorelin generates that GH pulse cleanly, without the cortisol rise that would work against lean tissue [1]. Whether the scale goes up or down depends on which lever dominates and on diet and training — which is exactly why community reports are mixed, and why no honest source can promise a direction.
What the animal data shows about body weight
The most direct body-weight finding is recent and points toward weight defence, not gain. In the 2024 ferret study, intraperitoneal ipamorelin (1–3 mg/kg) inhibited cisplatin-induced body-weight loss by roughly 24% during the delayed phase [5] — meaning it helped animals hold onto weight they would otherwise have lost to chemotherapy. On the structural side, the rat bone-growth study showed ipamorelin building skeletal tissue in a dose-dependent way, from 42 to 52 µm/day of long-bone growth, without raising systemic IGF-1 [4]. Read together, the animal record describes a compound that supports and reshapes body mass — defending weight under catabolic stress and adding skeletal growth — rather than one that simply piles on fat. But these are animals, in specific stress models, and they don't translate into a human prediction.
What people report about weight
Community reports — anecdotal, not clinical evidence, with doses and product quality unknown — split along the two levers. On the appetite side, increased hunger in the hours after injection is reported occasionally, described as milder than with older peptides but real enough that some users managing intake find it unwelcome. On the body-composition side, some users report a gradual shift toward a leaner appearance from roughly week five to week twelve with consistent use, openly confounded by diet and training. Mild, transient water retention or puffiness in the first few weeks is also reported occasionally, which can read as 'weight gain' on the scale without being fat. None of this is a clinical finding; it is collected for context, and it underscores that the direction is individual.
Does cjc-1295 ipamorelin work for body composition?
The honest position is that the CJC-1295/ipamorelin combination has never been tested as a unit in a controlled human trial for body composition or any other outcome — its rationale rests on the separate pharmacology of each peptide [1], and ipamorelin's own human record is one pharmacokinetic study [2] and one failed efficacy trial [3]. The mechanism is coherent and the animal signals (bone growth, weight defence) are real [4][5], but 'works' in the sense of a proven human body-composition result is not established. Anyone reading this should weigh a coherent mechanism and animal data against the complete absence of a controlled human body-composition trial — and against the fact that it is unapproved and banned in sport.